Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Marinus Pharmaceuticals Inc MRNS

Healthcare
Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of... see more

Recent & Breaking News (NDAQ:MRNS)

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Marinus Pharmaceuticals

Newsfile 11 days ago

The Schall Law Firm Initiates Investigation Into Allegations Against Marinus Pharmaceuticals, Inc. And Urges Investors Who Have Incurred Losses To Reach Out

Accesswire 11 days ago

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Marinus Pharmaceuticals, Inc. Investors - MRNS

Business Wire 12 days ago

The Schall Law Firm Begins Probe Into Claims Against Marinus Pharmaceuticals, Inc. And Encourages Investors With Losses To Make Contact

Accesswire 12 days ago

The Schall Law Firm Initiates Investigation into Allegations Against Marinus Pharmaceuticals, Inc. and Urges Investors with Losses to Reach Out

Accesswire 13 days ago

MRNS ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire 13 days ago

IMPORTANT ACTION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire June 2, 2024

IMPORTANT ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire June 1, 2024

IMPORTANT ACTION UPDATE: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 31, 2024

IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 30, 2024

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 29, 2024

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 28, 2024

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 27, 2024

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 26, 2024

IMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 25, 2024

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 24, 2024

IMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 23, 2024

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 22, 2024

DEADLINE ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 21, 2024

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 20, 2024